alt  

Antoine Tarral, Head of HAT Clinical Program, DNDi

Dr Antoine Tarral joined DNDi as Head of HAT (Human African Trypanosomiasis) in November 2010. Dr Tarral, who most recently served as Head of Clinical pharmacology at NOVEXEL SA, in charge of development of new antibiotics (phase 1 and phase 2), has around 15 years of Clinical pharmacology experience in pharma industry, as well as in CROs. 

From 1991 until 2006, Dr Tarral held various positions at Sandoz (now Novartis) and Biotrial as investigator in healthy volunteers studies and Chief Medical Officer of phase 1 units.

Dr Tarral completed post-doctoral pharmacology at La Pitié Salpetrière hospital, Paris, in neuro-psycho-pharmacology after earning his M.D. degree at the university of Nancy.